Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437102 | 0.83 | SMN1; SMN2 (0.37) | SMN1; SMN2ADRB2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL7914435 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2ADRB2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL6300137 | 0.71 | SMN1; SMN2 (0.47) | SMN1; SMN2ADRB2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL6299123 | 0.71 | ALDH1A1 (0.44) | SMN1; SMN2ADRB2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL22533879 | 0.68 | CHEK2 (0.49) | SMN1; SMN2ADRB2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL6298821 | 0.67 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL6299294 | 0.66 | MAPK1 (0.42) | SMN1; SMN2ALDH1A1HSP90AA1ESR2TDP1 | |
| SCHEMBL13594653 | 0.64 | ADRB2 (0.52) | SMN1; SMN2ADRB2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL13911135 | 0.63 | SMN1; SMN2 (0.39) | SMN1; SMN2ADRB2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL805045 | 0.63 | NUDT1 (0.60) | SMN1; SMN2HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | SMN1; SMN2 1017/4885ADRB2 32/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.